FDA Advises Caution, Consultation Before Using 99.99% Germ-Killing Claims On Sanitizers

Manufacturers considering use of the popular 99.99% germ-kill claim on hand sanitizer products should consult the Office of Compliance, said Division of Nonprescription Drug Products director Theresa Michele during a recent industry workshop. “Be very, very cautious about the claims you are making,” she said.

Hand Sanitizer

The claim “kills 99.99% of germs” is commonplace in the US hand sanitizer and antiseptic wipes marketplace, but its use is becoming increasingly problematic for manufacturers.

Proposed class actions in federal courts are testing the 99.99% germ-killing statement under false-advertising and other consumer protection laws, arguing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.